2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
Open accessAbstract
Background The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol recommends moderate- to high-intensity statins for patients with atherosclerotic cardiovascular disease but departs from the traditional treat-to-target approach. Whether percent low-density lipoprotein cholesterol (LDL-C) reduction or attained LDL-C levels add incremental prognostic value to statin dose is not known.Methods Patients in the Treating to New Targets (TNT), Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL), and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trials (patient-level data) randomized to a statin arm (atorvastatin 80 mg/10 mg or simvastatin 20 mg) were chosen. Patients were divided into groups based on attained LDL-C levels (≤70 vs >70 mg/dL) and percent LDL-C reduction (≥50% vs <50%). Primary outcome was major cardiovascular event defined as death due to coronary heart disease, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. Incremental prognostic value was assessed by using a forward conditional Cox proportional hazards model. Two models were tested: Model 1: Step 1 statin dose; Step 2 add attained LDL-C levels (continuous variable); Step 3 add percent LDL-C reduction (continuous variable). Model 2: Steps 2 and 3 were reversed.Results Among 13,937 patients included in this study, percent LDL-C reduction added incremental prognostic value over both statin dose and attained LDL-C levels (global chi-square increased from 3.64 to 26.1 to 47.5; P <.0001). However, attained LDL-C level did not provide incremental prognostic value over statin dose and percent LDL-C reduction (global chi-square increased from 3.64 to 47.5 to 47.5; P <.0001 and .94, respectively). Among patients with attained LDL-C ≤70 mg/dL, those with percent LDL-C reduction of <50% had a significantly higher risk of primary outcome (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.16-1.97; P = .002) and stroke (HR, 2.07; 95% CI, 1.46-2.93; P <.0001) and a numerically higher risk of death (HR, 1.37; 95% CI, 0.98-1.90; P = .06) when compared with the group with percent LDL-C reduction of ≥50%.Conclusions In patients with atherosclerotic cardiovascular disease, percent LDL-C reduction provides incremental prognostic value over statin dose and attained LDL-C levels. However, the attained LDL-C level does not provide additional prognostic value over statin dose and percent LDL-C reduction.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A significant difference in the risk of cardiovascular events was not seen when the LDL-C level was < 80 mg/dL.
“A significant difference in the risk of cardiovascular events was not seen when the LDL-C level was < 80 mg/dL.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [633]
In patients with LDL-C levels ≥ 120 mg/dL, the risk of the incidence of cardiovascular events was 1.74 times greater than in patients with LDL-C levels of 80-99 mg/dL.
“In addition, in patients with LDL-C levels ≥ 120 mg/dL, the risk of the incidence of cardiovascular events was 1.74 times greater than in patients with LDL-C levels of 80–99 mg/dL, which was a significant difference.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [633]
The incidence of cardiovascular events was significantly lower with the potent statin than with the standard statin in the CREDO-Kyoto Registry Cohort-2.
“The incidence of cardiovascular events was significantly lower with the potent statin than with the standard statin.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [633]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 15 · Cited by 51
- Authors
- Bangalore, S., Fayyad, R., Kastelein, J. J., Laskey, R., Amarenco, P., DeMicco, D. A., & Waters, D. D.
- Affiliations
- New York University (US)
- Pfizer (United States) (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Sorbonne Université (FR)
- San Francisco General Hospital (US)
- Corresponding author
- Bangalore, Sripal
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 129
- Issue
- 4
- Pages
- 384-391
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2163915271
- Cited by
- 51
- References
- 15
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 1 · 2019: 4 · 2018: 9 · 2017: 2 · 2016: 8 · 2015: 1
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- LDL cholesterol, statin dose, treat-to-target, cardiovascular prognosis, major adverse cardiovascular events, atorvastatin, simvastatin, atherosclerotic cardiovascular disease, ACC/AHA cholesterol guidelines, TNT trial, IDEAL trial, SPARCL trial, stroke risk
- MeSH terms
- Atorvastatin, Aged, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Prognosis, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review